News
Kite claims a first for CAR-T Tecartus in adult leukaemia
The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an
